Key Highlights

• Mangoceuticals Inc. (NASDAQ: MGRX) sold 850,000 restricted common shares in a private placement.

• The transaction generated $272,000 at $0.32 per share.

• Shares include piggyback registration rights for one year.

• No underwriters or commissions were involved in the offering.

Mangoceuticals Inc. (NASDAQ: MGRX) has secured fresh capital through a private stock sale. The healthcare company issued restricted shares to an accredited investor, marking its latest effort to strengthen its financial position.

Deal Terms Unveiled

The company sold 850,000 restricted common shares at $0.32 per share. The transaction closed on June 29, 2026, bringing in $272,000 without public solicitation. Investors received standard representations and warranties under the agreement.

Investor Protections

Shares come with piggyback registration rights valid for one year. This allows the investor to include the securities in future public offerings by Mangoceuticals. The terms reflect common practices in private placements to attract accredited backers.

Stock Restrictions Apply

The securities remain unregistered under the Securities Act of 1934. They carry transfer restrictions and require a legend noting their unregistered status. Resale is prohibited without registration or an applicable exemption.

No Underwriting Fees

Mangoceuticals handled the offering directly without intermediaries. The company paid no underwriting discounts or commissions. This approach reduces costs but limits distribution to pre-identified investors.

Compliance Requirements

The transaction follows SEC regulations for private securities sales. Mangoceuticals filed the necessary disclosures to meet reporting obligations. The deal avoids the complexities of a public offering while raising needed capital.

Market Context

The healthcare sector continues to attract private investment amid regulatory scrutiny. Mangoceuticals’ placement aligns with industry trends where companies seek flexible funding options. The $0.32 share price reflects current market conditions for micro-cap stocks.

Future Implications

The capital infusion may support Mangoceuticals’ operational expansion. Investors will monitor how the company deploys the funds in its growth strategy. Registration rights could lead to future liquidity events for shareholders.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.